机译:Bevacizumab和PACLitaxel-carboplatin化疗和继发性,铂敏感卵巢癌中的继发性细胞诊断(NRG肿瘤学/妇科肿瘤学研究GOG-0213):多期,开放标签,随机,第3阶段试验
Univ Texas MD Anderson Canc Ctr Dept Gynecol Oncol &
Reprod Med Houston TX 77030 USA;
Univ Buffalo NRG Oncol Gynecol Oncol Grp Stat Data Ctr Buffalo NY USA;
Univ Cincinnati Dept Obstet &
Gynecol Cincinnati OH 45221 USA;
Mem Sloan Kettering Canc Ctr Gynecol Med Oncol Serv 1275 York Ave New York NY 10021 USA;
Johns Hopkins Kimmel Canc Ctr Dept Obstet &
Gynecol Baltimore MD USA;
Univ Oklahoma Dept Obstet &
Gynecol Oklahoma City OK USA;
Sungkyunkwayn Univ Samsung Med Ctr Dept Obstet &
Gynecol Sch Med Seoul South Korea;
Saitama Med Univ Int Med Ctr Dept Obstet &
Gynecol Hidaka Japan;
Irvine Med Ctr Dept Obstet &
Gynecol Orange CA USA;
Ohio State Univ Dept Obstet &
Gynecol James Canc Hosp Columbus OH USA;
Univ Colorado Sch Med Dept Obstet &
Gynecol Denver CO USA;
Fox Chase Canc Ctr Dept Obstet &
Gynecol 7701 Burholme Ave Philadelphia PA 19111 USA;
Women &
Infants Hosp Rhode Isl Dept Obstet &
Gynecol Providence RI USA;
Univ Texas MD Anderson Canc Ctr Dept Gynecol Oncol &
Reprod Med Houston TX 77030 USA;
Univ Buffalo NRG Oncol Gynecol Oncol Grp Stat Data Ctr Buffalo NY USA;
Palo Alto Med Fdn Sutter Res Inst Calif Pacific Gynecol Canc Program San Francisco CA USA;
Womens Canc Ctr Las Vegas NV USA;
Univ Oklahoma Dept Obstet &
Gynecol Oklahoma City OK USA;
机译:Bevacizumab和PACLitaxel-carboplatin化疗和继发性,铂敏感卵巢癌中的继发性细胞诊断(NRG肿瘤学/妇科肿瘤学研究GOG-0213):多期,开放标签,随机,第3阶段试验
机译:Bevacizumab和PACLitaxel-carboplatin化疗和继发性,铂敏感卵巢癌中的继发性细胞诊断(NRG肿瘤学/妇科肿瘤学研究GOG-0213):多期,开放标签,随机,第3阶段试验
机译:Bevacizumab和PACLitaxel-carboplatin化疗和继发性,铂敏感卵巢癌中的继发性细胞诊断(NRG肿瘤学/妇科肿瘤学研究GOG-0213):多期,开放标签,随机,第3阶段试验
机译:贝伐单抗和紫杉醇-卡铂化疗和复发性铂敏感型卵巢癌的继发细胞减少(NRG肿瘤/妇科肿瘤组研究GOG-0213):一项多中心开放标签随机3期试验
机译:经常性,铂敏感卵巢,原发性腹膜和输卵管癌症中的Pegymated脂质体Doxorubicin(PLD),卡铂,Bevacizumab和Veliparib的一期试验:NRG肿瘤学/妇科肿瘤组研究